(Q39710538)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

14 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Targeting neural-restrictive silencer factor sensitizes tumor cells to antibody-based cancer immunotherapy in vitro via multiple mechanisms (English)

1 reference

14 September 2017

1 reference

Martin V Kolev

1

0 references

author name string

Marieta M Ruseva

series ordinal

2

1 reference

14 September 2017

B Paul Morgan

series ordinal

3

1 reference

14 September 2017

Rossen M Donev

series ordinal

4

1 reference

14 September 2017

language of work or name

English

0 references

publication date

26 April 2010

1 reference

14 September 2017

published in

Journal of Immunology

1 reference

14 September 2017

volume

184

1 reference

14 September 2017

issue

11

1 reference

14 September 2017

page(s)

6035-6042

1 reference

Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma

14 September 2017

cites work

2 references

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1158/0008-5472.CAN-07-6828

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation

2 references

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1093/NAR/GKQ013

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Recruitment of heterogeneous nuclear ribonucleoprotein A1 in vivo to the LMP/TAP region of the major histocompatibility complex.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Complement. First of two parts

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Modulation of protective T cell immunity by complement inhibitor expression on tumor cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway an

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

A role for SC35 and hnRNPA1 in the determination of amyloid precursor protein isoforms

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Mitosis-specific phosphorylation of nucleolin by p34cdc2 protein kinase

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Molecular mechanisms regulating protein kinase Czeta turnover and cellular transformation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

p53 regulates cellular resistance to complement lysis through enhanced expression of CD59

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Nucleolin is a protein kinase C-zeta substrate. Connection between cell surface signaling and nucleus in PC12 cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Monoclonal antibody therapy of cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.4049/JIMMUNOL.1000045

Identifiers

DOI

10.4049/JIMMUNOL.1000045

1 reference

14 September 2017

1 reference